

Matteo Serino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9404957/publications.pdf>

Version: 2024-02-01

58
papers

7,344
citations

101543

36
h-index

133252

59
g-index

71
all docs

71
docs citations

71
times ranked

12134
citing authors

#	ARTICLE	IF	CITATIONS
1	Intestinal gluconeogenesis shapes gut microbiota, fecal and urine metabolome in mice with gastric bypass surgery. <i>Scientific Reports</i> , 2022, 12, 1415.	3.3	4
2	Microbiota medicine: towards clinical revolution. <i>Journal of Translational Medicine</i> , 2022, 20, 111.	4.4	87
3	Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. <i>Microbiome</i> , 2021, 9, 104.	11.1	70
4	The Genotoxin Colibactin Shapes Gut Microbiota in Mice. <i>MSphere</i> , 2020, 5, .	2.9	34
5	Evolution of Gut Microbiome and Metabolome in Suspected Necrotizing Enterocolitis: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2278.	2.4	16
6	Active thrombin produced by the intestinal epithelium controls mucosal biofilms. <i>Nature Communications</i> , 2019, 10, 3224.	12.8	39
7	Structure function relationships in three lipids A from the <i>Ralstonia</i> genus rising in obese patients. <i>Biochimie</i> , 2019, 159, 72-80.	2.6	13
8	A Two-Week Treatment with Plant Extracts Changes Gut Microbiota, Caecum Metabolome, and Markers of Lipid Metabolism in ob/ob Mice. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1900403.	3.3	16
9	SCFAs – the thin microbial metabolic line between good and bad. <i>Nature Reviews Endocrinology</i> , 2019, 15, 318-319.	9.6	74
10	Oral microbiota-induced periodontitis: a new risk factor of metabolic diseases. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 449-459.	5.7	57
11	Molecular Paths Linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections. <i>Journal of Molecular Biology</i> , 2018, 430, 581-590.	4.2	22
12	Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity. <i>Molecular Nutrition and Food Research</i> , 2018, 62, 1700721.	3.3	73
13	Oral health and microbiota status in professional rugby players: A case-control study. <i>Journal of Dentistry</i> , 2018, 79, 53-60.	4.1	16
14	Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. <i>Nature Medicine</i> , 2018, 24, 1070-1080.	30.7	465
15	Periodontitis induced by <i>Porphyromonas gingivalis</i> drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. <i>Gut</i> , 2017, 66, 872-885.	12.1	210
16	Young microbes for adult obesity. <i>Pediatric Obesity</i> , 2017, 12, e28-e32.	2.8	15
17	Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice. <i>Diabetologia</i> , 2017, 60, 690-700.	6.3	52
18	Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. <i>Nature Medicine</i> , 2017, 23, 850-858.	30.7	1,165

#	ARTICLE	IF	CITATIONS
19	Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism. <i>Molecular Systems Biology</i> , 2017, 13, 921.	7.2	43
20	Gestational diabetes is associated with changes in placental microbiota and microbiome. <i>Pediatric Research</i> , 2016, 80, 777-784.	2.3	104
21	Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G1091-G1101.	3.4	20
22	Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. <i>Hepatology</i> , 2016, 64, 2015-2027.	7.3	230
23	MicroRNAs: Decoders of Dysbiosis into Metabolic Diseases?. <i>Journal of Diabetes & Metabolism</i> , 2016, 7, .	0.2	1
24	Defective <i>NOD2</i> peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance. <i>EMBO Molecular Medicine</i> , 2015, 7, 259-274.	6.9	160
25	Gut Microbiota Interacts With Brain Microstructure and Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4505-4513.	3.6	130
26	The Gut Microbiota Regulates Intestinal CD4 ⁺ T Cells Expressing ROR γ t and Controls Metabolic Disease. <i>Cell Metabolism</i> , 2015, 22, 100-112.	16.2	248
27	Intestinal permeability – a new target for disease prevention and therapy. <i>BMC Gastroenterology</i> , 2014, 14, 189.	2.0	1,187
28	Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression. <i>International Journal of Obesity</i> , 2014, 38, 737-745.	3.4	22
29	Managing the manager: Gut microbes, stem cells and metabolism. <i>Diabetes and Metabolism</i> , 2014, 40, 186-190.	2.9	14
30	Far from the Eyes, Close to the Heart: Dysbiosis of Gut Microbiota and Cardiovascular Consequences. <i>Current Cardiology Reports</i> , 2014, 16, 540.	2.9	81
31	A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction. <i>Diabetologia</i> , 2013, 56, 2524-2537.	6.3	109
32	The gut microbiota profile is associated with insulin action in humans. <i>Acta Diabetologica</i> , 2013, 50, 753-761.	2.5	50
33	Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. <i>Molecular Metabolism</i> , 2013, 2, 281-291.	6.5	84
34	Metagenome and metabolism: the tissue microbiota hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 61-70.	4.4	112
35	Study of lactoferrin gene expression in human and mouse adipose tissue, human preadipocytes and mouse 3T3-L1 fibroblasts. Association with adipogenic and inflammatory markers. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1266-1275.	4.2	36
36	Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. <i>Gut</i> , 2012, 61, 543-553.	12.1	511

#	ARTICLE	IF	CITATIONS
37	Intestinal MicrobiOMICS to Define Health and Disease in Human and Mice. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 746-758.	1.6	34
38	Microbes On-Air. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, S27-S28.	2.2	15
39	Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. <i>International Journal of Obesity</i> , 2012, 36, 1442-1449.	3.4	164
40	High-Fat Diet Induces Periodontitis in Mice through Lipopolysaccharides (LPS) Receptor Signaling: Protective Action of Estrogens. <i>PLoS ONE</i> , 2012, 7, e48220.	2.5	67
41	Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver. <i>Journal of Hepatology</i> , 2011, 54, 975-983.	3.7	127
42	Resveratrol Increases Glucose Induced GLP-1 Secretion in Mice: A Mechanism which Contributes to the Glycemic Control. <i>PLoS ONE</i> , 2011, 6, e20700.	2.5	124
43	Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. <i>Acta Diabetologica</i> , 2011, 48, 257-273.	2.5	199
44	Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. <i>Diabetologia</i> , 2011, 54, 3055-3061.	6.3	283
45	Gut microbiota and metabolic diseases: myth or reality?. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2011, 4, 75-77.	0.5	0
46	CD14 Modulates Inflammation-Driven Insulin Resistance. <i>Diabetes</i> , 2011, 60, 2179-2186.	0.6	83
47	Lipid-Induced Peroxidation in the Intestine Is Involved in Glucose Homeostasis Imbalance in Mice. <i>PLoS ONE</i> , 2011, 6, e21184.	2.5	9
48	Gut microbiota and metabolic diseases: myth or reality?. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010, 4, 75-77.	0.5	0
49	The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases ?. <i>Frontiers in Bioscience - Landmark</i> , 2009, 14, 5107.	3.0	52
50	Accelerated Lipid-Induced Atherogenesis in Galectin-3-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 831-836.	2.4	85
51	A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism. <i>Current Opinion in Pharmacology</i> , 2009, 9, 744-752.	3.5	47
52	Intestinal microflora and metabolic diseases. <i>Diabetes and Metabolism</i> , 2009, 35, 262-272.	2.9	67
53	Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 54-60.	2.6	23
54	Tissue Inhibitor of Metalloproteinase 3 Deficiency Causes Hepatic Steatosis and Adipose Tissue Inflammation in Mice. <i>Gastroenterology</i> , 2009, 136, 663-672.e4.	1.3	103

#	ARTICLE	IF	CITATIONS
55	Flore intestinale: de nouveaux concepts pour la régulation du métabolisme énergétique. <i>Sang Thrombose Vaisseaux</i> , 2009, 21, 322-333.	0.1	0
56	Mice Heterozygous for Tumor Necrosis Factor- α Converting Enzyme Are Protected From Obesity-Induced Insulin Resistance and Diabetes. <i>Diabetes</i> , 2007, 56, 2541-2546.	0.6	104
57	We-P11:122 Increased TNF-alpha in patients affected by coronary artery disease is associated to undiagnosed impaired glucose metabolism. Role of pioglitazone. <i>Atherosclerosis Supplements</i> , 2006, 7, 372-373.	1.2	0
58	Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF- α . <i>Journal of Clinical Investigation</i> , 2005, 115, 3494-3505.	8.2	141